---
title: "Mizuho Securities Reaffirms Their Buy Rating on IN8bio (INAB)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295601292.md"
description: "Mizuho Securities analyst Uy Ear reaffirmed a Buy rating on IN8bio (INAB) with a $4.00 price target. Ear, a 4-star analyst in the Healthcare sector, maintains this stance despite IN8bio's broader Strong Buy consensus and $5.00 average price target from TipRanks."
datetime: "2026-08-12T01:55:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295601292.md)
  - [en](https://longbridge.com/en/news/295601292.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295601292.md)
generator: "portal-rs"
---

# Mizuho Securities Reaffirms Their Buy Rating on IN8bio (INAB)

Mizuho Securities analyst Uy Ear maintained a Buy rating on IN8bio yesterday and set a price target of $4.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

According to TipRanks, Ear is a 4-star analyst with an average return of 7.8% and a 44.95% success rate. Ear covers the Healthcare sector, focusing on stocks such as Alkermes, Evolus, and Arcutis Biotherapeutics.

IN8bio has an analyst consensus of Strong Buy, with a price target consensus of $5.00.

### Related Stocks

- [INAB.US](https://longbridge.com/en/quote/INAB.US.md)
- [MFG.US](https://longbridge.com/en/quote/MFG.US.md)
- [8411.JP](https://longbridge.com/en/quote/8411.JP.md)
- [ALKS.US](https://longbridge.com/en/quote/ALKS.US.md)
- [EOLS.US](https://longbridge.com/en/quote/EOLS.US.md)
- [ARQT.US](https://longbridge.com/en/quote/ARQT.US.md)

## Related News & Research

- [TD Cowen Keeps Their Buy Rating on Amgen (AMGN)](https://longbridge.com/en/news/298357051.md)
- [Structure Therapeutics: Buy Rating Reaffirmed on Promising Obesity Pipeline and Extended Data, Price Target Maintained at $104](https://longbridge.com/en/news/298369077.md)
- [Morgan Stanley Reaffirms Their Buy Rating on Ferrari (RACE)](https://longbridge.com/en/news/298546483.md)
- [J.P. Morgan Sticks to Its Buy Rating for UniCredit SpA (UNCFF)](https://longbridge.com/en/news/298272460.md)
- [Dyne Therapeutics: Buy Rating Backed by Late-Stage Muscle Disease Platform, Multibillion-Dollar Opportunities, and Dual-Path Approval Strategy](https://longbridge.com/en/news/298319347.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**